Nasdaq
$25.00▼ 1.94%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $4.00BShares out 1.600M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
36- 3d agoAfter-hours26.10.22 07:364Ownership#●●●#●●●
Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp insider Julie Rubinstein reported a change in share ownership effective October 19, 2026. This filing is a standard Form 4 disclosure regarding executive equity transactions.…more
$25.00-1.94%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.16After-hours26.10.17 08:214Ownership
Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp insider Julie Rubinstein filed a Form 4 on October 16, 2026, reporting changes in beneficial ownership of securities as of October 14, 2026. This filing serves as an official record of the insider's equity position changes.…more
$25.00-1.94%vs prev closeView filingShare - 10.13After-hours26.10.14 08:054Ownership
Adaptive Biotechnologies Corp
Insider Julie Rubinstein of Adaptive Biotechnologies Corp reported a change in beneficial ownership of securities effective October 9, 2026. This filing serves as a standard disclosure of changes in the insider's equity holdings.…more
$25.00-1.94%vs prev closeView filingShare
35 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.14After-hours26.10.15 05:05#●●●#●●●
Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results…more
Adaptive Biotechnologies announced that it will release its financial results for the third quarter of 2026 after the market closes on November 4, 2026. The company will host a conference call to discuss its quarterly financial performance and business updates.…more
$25.00-1.94%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.25Pre-market26.09.25 21:03
●●●●●●●● ●●●●● ●●●●●●
The International Myeloma Society has established a new consensus definition for myeloma cure, emphasizing the role of highly sensitive MRD testing. While Adaptive Biotechnologies' clonoSEQ is highlighted as a key tool for this standard, the news reflects clinical guideline updates rather than immediate financial performance.…more
$25.00-1.94%vs prev close - 9.17Pre-market26.09.17 21:00
●●●●●●●● ●●●●● ●●●●●●
The NCCN has updated its multiple myeloma clinical guidelines to include a dedicated framework for MRD testing, specifically naming Adaptive Biotechnologies' clonoSEQ as the preferred assay. This inclusion reinforces the clinical utility of the test and supports its role in standardized patient care.…more
$25.00-1.94%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report